STOCK TITAN

Marker Therapeutics (MRKR) Stock News, Mar-Aug 2023

MRKR NASDAQ

Marker Therapeutics, Inc. reports developments as a clinical-stage immuno-oncology company developing non-genetically modified Multi-Antigen Recognizing T cell therapies for hematologic malignancies and solid tumor indications. Its recurring company updates center on the MAR-T cell platform, MT-601 in lymphoma, MT-401-OTS as an off-the-shelf program, and pancreatic cancer research connected to technology developed at Baylor College of Medicine.

Company news also covers clinical observations from named studies, non-dilutive funding from government and cancer-research programs, scientific publications and medical-meeting presentations, quarterly financial results, conference participation, shareholder voting matters, and board governance changes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.08%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.75%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.87%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.85%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.04%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.59%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.84%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.97%
Tags
management
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.47%
Tags
none
Rhea-AI Summary

Marker Therapeutics (Nasdaq: MRKR) reported significant updates regarding its clinical programs and financial results for fiscal year 2022. The company received a $2 million grant from the FDA for the Phase 2 ARTEMIS trial of MT-401 in acute myeloid leukemia (AML) and cleared IND applications for MT-601 targeting metastatic pancreatic cancer and non-Hodgkin lymphoma. The improved T cell manufacturing process for MT-401 has yielded a production time reduction to 9 days and enhanced product efficacy. Financially, Marker reported a net loss of $29.9 million, down from $41.9 million in 2021, and had a cash position of $11.8 million at year-end.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.82%
Tags

FAQ

What is the current stock price of Marker Therapeutics (MRKR)?

Marker Therapeutics (MRKR) last closed at $1.09.

What is the market cap of Marker Therapeutics (MRKR)?

The market cap of Marker Therapeutics (MRKR) is approximately $18.2M.